GSK files for Japanese approval of its H1N1 vaccine
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has applied for approval of its H1N1 pandemic flu vaccine in Japan, under expedited regulatory procedures which will allow it to submit data from ongoing local clinical trials on a rolling basis.